NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Asciminib RMP Study

RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Chronic Myeloid Leukemia

Interventions: Asciminib

Countries: South Korea

This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion criteria

1. Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive Scemblix® treatment according to locally approval label
2. Patients who are willing to provide written informed consent prior to study enrollment

Exclusion criteria

1. Patients with contraindication according to locally approved label of Scemblix®
2. Patients who receive or are going to receive any investigational medicine during the observation period

Locations (17)

Wŏnju, Gangwon-do, South Korea
Anyang-si, Gyeonggi-do, South Korea
Bucheon-si, Gyeonggi-do, South Korea
Uijeongbu-si, Gyeonggi-do, South Korea
Gyeonggi-do, Korea, South Korea
Incheon, Korea, South Korea
Seoul, Korea, South Korea
Seoul, Seoul, South Korea
Seoul, Seoul, South Korea
Seoul, Yangcheon gu, South Korea
Suwon, Yeongtong Gu, South Korea
Jeollanam, South Korea
Pusan, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Taegu, South Korea